Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company engineered to pioneer targeted therapies for cardiorenal metabolic diseases driven by abnormally elevated or dysregulated aldosterone levels. Operating at the frontier of precision pharmacology, the company eliminates the therapeutic ceiling of legacy antihypertensive treatments—which routinely fail over 30 million U.S. patients suffering from uncontrolled or resistant hypertension—by developing lorundrostat, a novel, orally administered, highly selective aldosterone synthase inhibitor (ASI). Moving beyond broad-spectrum blood pressure medications and non-selective mineralocorticoid receptor antagonists, Mineralys Therapeutics equips healthcare systems with clinical-stage small molecules designed to stop aldosterone hyper-production directly at its enzymatic source, significantly reducing systemic vascular strain and organ damage with targeted, once-daily precision. Under the hood, its clinical development engine—bolstered by Phase 2/3 trial data (Target-HTN), biomarker-driven patient selection, and robust cardiorenal clinical protocols—natively targets resistant hypertension, chronic kidney disease (CKD), and obstructive sleep apnea. What sets Mineralys Therapeutics apart is its laser focus on the root metabolic drivers of cardiovascular disease; by selectively inhibiting aldosterone synthesis while preserving systemic hormone balance, the firm enables clinicians to break treatment resistance, protect vital organ architecture, and set a new therapeutic standard in cardiovascular and renal health.